,,ii #aaith ,,congress #b;d ,session ,s4 #eeed ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,september #bd1 #bjbf,ms4 ,slotkin 7for herself and ,mrs4 ,britt7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to modernize and strengthen ,federal efforts to improve ovarian cancer awareness1 hereditary cancer risk assessment1 access to genetic counseling and testing1 and access to specialty care1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,ovarian ,cancer ,improving and ,modernizing ,prevention1 ,access1 ,care1 and ,testing ,act or the ,ovarian ,cancer ,,impact ,act4 #b4 ,findings ,congress finds the following3 7#a7 ,ovarian cancer remains one of the deadliest gynecologic cancers and is frequently diagnosed at an advanced stage4 7#b7 ,early recognition of symptoms1 access to genetic counseling and testing1 and timely referral to specialized care can improve outcomes for individuals diagnosed with ovarian cancer4 7#c7 ,significant disparities persist in access to gynecologic oncology services1 genetic counseling1 hereditary cancer risk assessment1 and specialty care1 particularly in rural and medically underserved communities4 7#d7 ,advances in genetic and genomic science present significant opportunities to improve prevention1 early detection1 treatment selection1 and survivorship outcomes4 7#e7 ,hereditary cancer syndromes1 including hereditary breast and ovarian cancer syndrome and ,lynch syndrome1 contribute significantly to ovarian cancer risk and may first be identified following a diagnosis of endometrial cancer4 7#f7 ,evidence-based genetic counseling and testing can inform treatment decisions1 guide preventive interventions1 and identify at-risk family members who may benefit from surveillance or risk-reducing care4 7#g7 ,increased public education1 provider awareness1 and access to specialty care are essential to improving outcomes for individuals affected by ovarian cancer and hereditary cancer syndromes4 #c4 ,reauthorization and improvement of ,johanna's ,law ,section #cag,p7d7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;b-#ag7;d77 is amended-- 7#a7 in paragraph 7#a7-- 7,a7 in subparagraph 7,a71 by inserting 1 in coordination with relevant programs of the ,health ,resources and ,services ,administration and the ,national ,cancer ,institute1 after ,the ,secretary2 and 7,b7 by adding at the end the following3 7,d7 ,enhanced outreach and education ,activities under the national campaign under subparagraph 7,a7 shall include-- 7i7 developing and disseminating culturally and linguistically appropriate public service announcements and educational materials directed toward populations at elevated risk based on race1 ethnicity1 genetic predisposition1 or family history2 7ii7 conducting targeted outreach activities for populations experiencing elevated risk of ovarian cancer or disparities in outcomes1 including populations with hereditary cancer syndromes and populations residing in rural and medically underserved communities2 7iii7 promoting awareness of hereditary cancer syndromes associated with ovarian cancer risk1 including hereditary breast and ovarian cancer syndrome and ,lynch syndrome1 and the availability of genetic counseling1 genetic testing1 and evidence-based risk-reducing interventions2 7iv7 disseminating information regarding coverage and benefits relating to genetic counseling1 genetic testing1 and risk-reducing interventions available under ,federal and private health insurance programs2 7v7 developing and distributing educational materials for patients and health care professionals regarding current evidence-based guidelines relating to hereditary cancer risk assessment1 genetic counseling1 genetic testing1 and referral to specialty care2 and 7vi7 developing and disseminating information for patients and health care providers on evidence-based ovarian cancer risk-reduction strategies1 including opportunistic salpingectomy and the circumstances in which such an intervention may be appropriate4 2 7#b7 by inserting after paragraph 7#d71 the following3 7#e7 ,demonstration projects 7,a7 ,in general ,the ,secretary shall award grants to carry out demonstration projects under this subsection to test and evaluate outreach strategies relating to ovarian cancer awareness1 hereditary cancer risk assessment1 genetic counseling1 genetic testing1 and access to specialty care4 7,b7 ,preference ,in awarding grants under this paragraph1 the ,secretary shall give preference to applicants experienced in serving rural1 medically underserved1 or high-risk populations4 7,c7 ,eligible entities ,entities eligible to receive a grant under this paragraph shall include ,state1 local1 and ,tribal public health departments1 community health centers1 rural hospitals1 academic medical centers1 nonprofit organizations1 and other entities determined appropriate by the ,secretary4 7,d7 ,reports ,not later than #c years after the date on which grants are awarded under this paragraph1 and annually thereafter1 the ,secretary shall submit to ,congress a report that evaluates outcomes of projects carried out under this paragraph4 ,such reports shall identify barriers to care and contain best practices4 and 7#c7 by striking paragraph 7#f7 and inserting the following3 7#f7 ,authorization of appropriations ,for the purpose of carrying out this subsection1 there is authorized to be appropriated #bj1jjj1jjj for each of fiscal years #bjbg through #bjca4 4 #d4 ,rural access to ovarian cancer care 7a7 ,rural health care services outreach grants ,section #ccj;,a7e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bed;c7e77 is amended-- 7#a7 in paragraph 7#a71 by inserting 1 including with respect to ovarian cancer prevention1 diagnosis1 treatment1 survivorship services1 hereditary cancer risk assessment1 genetic counseling1 and care coordination1 after delivery of health care services2 and 7#b7 in paragraph 7#b77;,a71 by inserting or ,tribal communities before the semicolon4 7b7 ,expanding capacity for health outcomes ,section #ccj,n7b7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bed;c-#bj7;b77 is amended by inserting ovarian cancer1 after palliative care14 #e4 ,standards relating to benefits for genetic and genomic testing for1 early detection of1 and risk-reducing interventions with respect to ovarian cancer 7a7 ,in general ,part ,a of title ,,xxvii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg et seq47 is amended by inserting after section #bgbi the following new section3 #bgbi;,a4 ,standards relating to benefits for genetic and genomic testing for1 early detection of1 and risk-reducing interventions with respect to ovarian cancer 7a7 ,coverage relating to benefits for genetic and genomic testing 7#a7 ,in general ,a group health plan1 or a health insurance issuer offering group or individual health insurance coverage1 shall provide coverage to an enrollee-- 7,a7 who-- 7i7 has a personal history of ovarian cancer2 7ii7 has a personal history of endometrial cancer for whom genetic counseling or genetic testing is recommended under evidence-based clinical practice guidelines developed by the ,national ,comprehensive ,cancer ,network1 the ,american ,society of ,clinical ,oncology1 or the ,society of ,gynecologic ,oncology2 or 7iii7 has a family history indicative of hereditary ovarian cancer1 ,lynch syndrome1 or another hereditary cancer syndrome associated with increased ovarian cancer risk2 and 7,b7 for-- 7i7 genetic counseling by a certified provider 7in person or via telehealth72 7ii7 multi-gene panel testing for germline genetic mutations using next-generation sequencing or other comparable advanced diagnostic testing technologies1 as applicable2 7iii7 single syndrome1 single-gene mutation testing1 or targeted mutation testing if determined by the attending health care provider to be more appropriate2 and 7iv7 tumor genomic profiling or biomarker testing for somatic mutations using next-generation sequencing1 or other comparable advanced diagnostic testing technology1 as applicable4 7#b7 ,scope of testing ,testing required under this subsection shall include testing to detect-- 7,a7 genetic mutations in ,,brca#a and ,,brca#b genes2 7,b7 genetic mutations associated with ,lynch syndrome2 7,c7 mismatch repair deficiency1 microsatellite instability1 and other biomarkers recommended under evidence-based clinical practice guidelines for identification of ,lynch syndrome or other hereditary cancer syndromes associated with increased ovarian cancer risk2 7,d7 rearrangement analysis of all coding exons associated with ovarian cancer2 and 7,e7 additional mutations1 including mutations in the ,,brip#a1 ,,rad#ea;,c1 and ,,rad#ea;,d genes1 in accordance with evidence-based clinical practice guidelines addressing genetic testing1 screening1 and management of individuals with a personal history of ovarian cancer or a family history indicating or suspicious for increased ovarian cancer risk developed by the ,national ,comprehensive ,cancer ,network1 the ,american ,society of ,clinical ,oncology1 the ,society of ,gynecologic ,oncology1 or another nationally recognized oncology professional organization4 7#c7 ,application of guidelines ,in administering paragraph 7#b7 in the case of conflicting guidelines developed by more than one nationally recognized oncology professional organization1 the least restrictive of such guidelines shall apply4 7#d7 ,repeat or expanded testing ,a group health plan or health insurance issuer shall provide coverage of repeat or expanded testing if medically necessary and appropriate1 as determined by the treating health care provider4 7b7 ,coverage for early detection and risk-,reducing interventions ,a group health plan1 and a health insurance issuer offering group or individual health insurance coverage1 shall provide coverage for evidence-based early detection1 hereditary cancer risk management1 risk-reducing surgeries1 and other interventions intended to reduce the risk of ovarian cancer in individuals identified as being at elevated hereditary risk where indicated under nationally recognized oncology professional organization guidelines4 ,coverage under this subsection shall be provided regardless of whether the enrollee has a personal history of ovarian cancer or endometrial cancer4 7c7 ,rule of construction ,nothing in this section shall be construed to require an enrollee to receive testing1 early detection1 or risk-reducing interventions described in this section4 7d7 ,level and type of reimbursements ,nothing in this section shall be construed to prevent a group health plan or health insurance issuer from negotiating the level and type of reimbursement with a provider for care provided in accordance with this section4 7e7 ,provider education and implementation ,the ,secretary1 acting through the ,director of the ,centers for ,disease ,control and ,prevention and in consultation with the ,administrator of the ,health ,resources and ,services ,administration1 shall support activities to increase awareness among health care professionals regarding-- 7#a7 evidence-based guidelines for genetic counseling and genetic testing in individuals diagnosed with ovarian cancer or endometrial cancer2 7#b7 collection and assessment of family cancer history2 7#c7 appropriate referral pathways for genetic counseling and specialty care2 and 7#d7 coverage protections established under this section4 7f7 ,evaluation ,the ,secretary shall evaluate activities conducted under this section1 including-- 7#a7 providing for public awareness of ovarian cancer symptoms and hereditary cancer risk factors2 7#b7 providing provider awareness of evidence-based genetic counseling and testing guidelines2 7#c7 the utilization of genetic counseling and testing services2 7#d7 ensuring access to services in rural and medically underserved communities2 and 7#e7 whether barriers exist to the implementation of this section4 7g7 ,privacy protections ,the ,secretary shall ensure that this section is carried out in a manner that complies with all applicable ,federal and ,state privacy laws4 4 7b7 ,application to grandfathered health plans ,section #abea7;a77#d77;,a7 of the ,patient ,protection and ,affordable ,care ,act 7#db ,u4,s4,c4 #ahjaa7;a77#d77;,a77 is amended-- 7#a7 in the matter preceding clause 7i71 by striking 7as added by this title72 and 7#b7 by adding at the end the following3 7v7 ,section #bgbi;,a 7relating to standards relating to benefits for genetic and genomic testing for1 early detection of1 and risk-reducing interventions with respect to ovarian cancer74 4 7c7 ,effective date ,the amendments made by this section shall apply with respect to plan years beginning on or after the date that is #a year after the date of enactment of this ,act4 #f4 ,implementation and reporting 7a7 ,implementation plan ,not later than #ahj days after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall submit to ,congress an implementation plan outlining timelines1 agency responsibilities1 and performance benchmarks with respect to the amendments made by this ,act4 7b7 ,report ,not later than #c years after the date of enactment of this ,act1 and every #c years thereafter through fiscal year #bjcb1 the ,secretary of ,health and ,human ,services shall submit to ,congress a report that describes-- 7#a7 implementation activities under the amendments made by this ,act2 7#b7 the utilization of genetic counseling and testing services under such amendments2 7#c7 the utilization of risk-reducing interventions under such amendments2 7#d7 progress made in improving access to ovarian cancer care in rural and medically underserved communities2 and 7#e7 recommendations for further legislative or administrative action4